The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Treatment landscape for dual-refractory CLL: current strategies and future directions
Jacob Soumerai, MD, Massachusetts General Hospital, Boston, MA, discusses the current treatment landscape for patients with dual-refractory chronic lymphocytic leukemia (CLL) who have failed BTK inhibitors (BTKis) and BCL2 inhibitors. Dr Soumerai highlights the efficacy of non-covalent BTKis like pirtobrutinib, CAR T-cell therapies, and BTK degraders in this patient population. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
